By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


ACADIA Pharmaceuticals, Inc. 

3911 Sorrento Valley Boulevard

San Diego  California  92121   U.S.A.
Phone: 858-558-2871 Fax: 858-558-2872


Drug Discovery


Allergan  Discovery of alpha adrenergic drug candidates that may represent a significant breakthrough in the treatment of neuropathic pain.

Allergan  Develop and commercialize selective muscarinic drugs for the treatment of glaucoma.

Allergan  The third collaboration is designed to leverage ACADIA's R&D platform to discover and develop new therapeutics predominantly in the area of pain.

Sunovion Pharmaceuticals Inc.  ACADIA has formed a broad CNS collaboration with Sepracor for the discovery and development of new drug candidates against muscarinic receptors.

Company News
Acadia (ACAD) Announces FDA Advisory Committee Meeting To Review NUPLAZID (Pimavanserin) For The Treatment Of Parkinson’s Disease Psychosis 2/1/2016 11:13:51 AM
Acadia (ACAD) Appoints James (Randy) R. Owen, M.D., As Senior Vice President, Clinical Development And Chief Medical Officer 1/25/2016 7:39:32 AM
Acadia (ACAD) Appoints Jim Daly To Board Of Directors 1/11/2016 12:55:51 PM
Acadia (ACAD) To Present At The 34th Annual J.P. Morgan Healthcare Conference On January 12, 2016 1/7/2016 11:54:53 AM
Acadia (ACAD) Prices Public Offering Of Common Stock 1/7/2016 11:33:16 AM
Acadia (ACAD) Announces Proposed Public Offering Of Common Stock 1/6/2016 11:37:25 AM
Acadia (ACAD) Appoints Julian C. Baker To Board Of Directors 12/15/2015 11:10:52 AM
Acadia (ACAD) Appoints Srdjan (Serge) Stankovic, M.D., M.S.P.H., As Executive Vice President, Head Of Research And Development 11/30/2015 10:19:23 AM
Acadia (ACAD) Appoints Edmund P. Harrigan, M.D., To Board Of Directors 11/30/2015 10:17:27 AM
Acadia (ACAD) Reports Third Quarter 2015 Financial Results 11/6/2015 11:19:18 AM